- To bring to the market the oncology treatment drug.
- An affordable treatment for everyone.
- A safe therapy.
“Someone is sitting in the shade today because
someone planted a tree a long time ago“ - Warren Buffett
The year of foundation of the Company
Launch of the first product on the market
Payment of the first dividends
Countries of the project participants
Investments in a promising business with a turnover of more than $ 200 billion dollars a year
An opportunity to have access to all preparations and company developments at the lowest prices
The annual payment of dividends to investors of the company, after calculating the annual profit
The ability to transfer their shares in the company by inheritance
Participation in the creation of an important area in the safe therapy and treatment of many diseases
Profit from all development and investment tools of the company
in 2010, the company's share was worth $ 0.009, and after 9 years the price rose to $ 44 per share. An investment of $ 100 in Uber, after 9 years made a profit of $ 500,000
The company was founded in 1996. Initial investment in the company amounted to $ 25 million. The current capitalization of the company is about 1 trillion dollars. An investment of $ 100 in 1998 grew to $ 4,000,000 after 20 years.
Steve Jobs, Steve Wozniak, and Ron Wayne founded the company in 1976. Ron Wayne sold his 10% stake for $ 800 in 2 weeks. Today 10% of the company costs about $ 100 billion!
The company was founded in 1999. Attracted investments of $ 25,000,000. At the beginning of 2020, market capitalization exceeded $ 600 billion. $ 100 of investments grew to $ 2.4 million
Sanofi-Synthelabo announced that it has signed an agreement with Pfizer Inc. regarding the divestment of Aventis’ interests in Campto (irinotecan) in response to requests made by the competition authorities.Subject to the success of Sanofi-Synthelabo’s offer for Aventis, Pfizer will take over clinical studies for Campto that are currently conducted by Aventis, together with certain patents and other assets pertaining to territories where Pfizer currently markets irinotecan. The consideration for the whole transaction is of $620 million.
GlaxoSmithKline plc (LSE/NYSE: GSK) and TESARO Inc (NASDAQ: TSRO) today announced that the Companies have entered into a definitive agreement pursuant to which GSK will acquire TESARO, an oncology-focused company based in Waltham, Massachusetts, for an aggregate cash consideration of approximately $5.1 billion (£4.0 billion). The proposed transaction will significantly strengthen GSK’s pharmaceutical business, accelerating the build of GSK’s pipeline and commercial capability in oncology.
NEW YORK & BOULDER, Colo.--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and Array BioPharma Inc. (NASDAQ: ARRY) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Array, a commercial stage biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need. Pfizer has agreed to acquire Array for $48 per share in cash, for a total enterprise value of approximately $11.4 billion. The Boards of Directors of both companies have approved the merger.
Pfizer Inc. (NYSE:PFE) and Medivation, Inc. (NASDAQ:MDVN) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Medivation, a biopharmaceutical company focused on developing and commercializing small molecules for oncology, for $81.50 a share in cash for a total enterprise value of approximately $14 billion.
Johnson & Johnson
Merck & Co.
In 2004 – preclinical trials.
In 2006 - 2007 – clinical trials of the first and second phase.
In 2015 – development of a suppository, a new formula of the drug named FRAN.
What is the difference between FRAN and existing drugs?
The common properties of all chemotherapeutic drugs are high toxicity and a complete lack of selectivity of action, when the drug acts equally on healthy cells of the body and on cancer cells.
The advantage of our project is the uniqueness of the drug. Unlike all other antitumor drugs, FRAN is an absolutely safe drug of natural origin and it does not contain chemical modifiers. This fact determines the unique therapeutic properties of the drug, which will create a very high demand for it in the future.
Research, as well as the opinion of practicing oncologists, suggests that the combination of positive properties makes it unique, without worthy competitors in the antitumor market. This is proved by preclinical trials, clinical trials and more than 500 people who have already been treated with FRAN.
By the sum of the positive qualities combining high antitumor efficacy, absolute selectivity towards tumor cells and complete absence of toxicity, the drug FRAN is unique in comparison with the well-known chemotherapeutic drugs.
The development of the drug FRAN is a revolutionary solution and it opens up a new direction in the science of creating drugs for the safe treatment of cancer and, which is important, it carries out prophylaxis to restore immunity in order to destroy cancer cells at an early stage.
Already, the drug can be ordered by contacting our representatives on our website ufgroup.proClose
Yllo Messenger is a mobile application for instant messaging, crypto assets and business. Decentralized messenger built on cluster architecture. It does not have a central server. In addition to ordinary communication, it has a built-in crypto wallet for storing and transferring various cryptocurrencies
Crypto platform. On the Yllo platform you can issue any digital asset: with a unique name, logo and rules. The issuer himself sets the parameters of the total emission, inflation, burning, commission, distribution, initial price and any other properties of the asset.
Branding. Any element of the platform (instant messenger, notes, wallet for PC) can be branded as a client, as a personal tool based on Yllo.
Cryptocurrency exchange XLT.One - is a platform for the exchange of classic cryptocurrencies and all crypto assets created in Yllo.Close